PURPOSE: To assess modified folinic acid/leucovorin, fluorouracil, irinotecan, oxaliplatin (FOLFIRINOX [mFFX]) versus gemcitabine/nab-paclitaxel (GnP) in de novo metastatic pancreatic ductal adenocarcinoma (PDAC) and explore predictive biomarkers. PATIENTS AND METHODS: Patients were randomly assigned 1:1 to mFFX or GnP with exclusion of germline pathogenic variants in BRCA1/2 or PALB2 . The primary end point was progression-free survival (PFS) between arms with 0.3 significance. The per-protocol (PP) population included patients who received one dose of chemotherapy. Pretreatment biopsies underwent whole-genome/transcriptome sequencing and patient-derived organoid (PDO) development, providing correlate recommendations at a molecular tumor board and outcomes assessed according to RNA signatures (basal-like v classical). RESULTS: Of 160 patients randomly assigned (80 mFFX, 80 GnP), 140 patients were in the PP population (71 mFFX, 69 GnP), with median follow-up of 8.3 months. The median PFS was 4.0 months for mFFX versus 5.3 months for GnP (hazard ratio [HR], 1.37 [95% CI, 0.97 to 1.92]; P = .069) in intention-to-treat. Median overall survival (OS) was 8.5 months with mFFX and 9.7 months with GnP (HR, 1.57 [95% CI, 1.08 to 2.28]; P = .017). Genomic data were generated in 94%, transcriptomes in 74%, and PDOs in 50%. The median PFS for those with basal-like was 3.0 (mFFX) and 5.5 (GnP) months ( P = .17), and classical PDAC was 6.3 (mFFX) versus 5.4 (GnP) months ( P = .36). The median OS in basal-like was 7.5 (mFFX) and 8.9 (GnP) months ( P = .75) versus in classical OS was 9.7 (mFFX) and 13.9 (GnP) months ( P = .047). Overall, 75 (54%) of patients received second-line treatment, 33/75 (44%) correlate-guided. The median time on second-line treatment was only 2.1 months with a median OS of 5.4 months for a correlate-guided choice versus 4.4 months on a standard chemotherapy approach ( P = .45). CONCLUSION: In the phase II Pancreatic Adenocarcinoma Signature Stratification for Treatment-01 (PASS-01) trial population, PFS was similar between GnP and mFFX; however, OS and safety trends favored GnP. The second-line setting appears inadequate to offer precision choices, given the short survival observed.
Objective: We conducted a systematic review and meta-analysis to evaluate the relationship between No Evidence of Disease Activity (NEDA) and no long-term disability progression on low and high efficacy therapy in relapsing-remitting multiple sclerosis (RRMS). Methods: MEDLINE, Embase, and the Cochrane Database were searched from January 1, 2006 to January 26, 2021. We selected studies which evaluated NEDA-3 (no relapse, new MRI lesion, or confirmed disability progression) at one or two years and had a minimum of four years’ follow-up for determination of disability progression. Data were extracted by two independent reviewers and were meta-analyzed using a random effects model. Primary outcome of no disability progression was defined as no confirmed progression on the Expanded Disability Status Scale (EDSS) during follow-up. We assessed the odds ratio for no disability progression with NEDA vs. Evidence of Disease Activity (EDA). Positive predictive value of NEDA for no disability progression was summarized for studies with prevalence of no progression >80% vs. <80% separately. Results: We included 29 studies in our qualitative synthesis of which 27 (16 low efficacy, 11 high efficacy) were included in the meta-analysis (n=10,935 participants). Median follow-up was 5.6 years (IQR: 4.3, 8.0 years). The pooled odds ratios for no progression with NEDA-3 vs. EDA were 2.32 (95% CI: 1.58-3.42; I2=73%) for low efficacy therapy and 3.19 (1.86-5.47; I2=86%) for high efficacy therapy. Among studies with prevalence of no progression at follow-up >80%, the pooled positive predictive value for low efficacy therapy was 91% (95% CI: 89-93%) and for high efficacy therapy was 92% (95% CI: 88-94%). Among studies with prevalence of no progression <80%, the pooled positive predictive value for low efficacy therapy was 81% (95% CI: 75-86%) and for high efficacy therapy was 86% (95% CI: 80-90%). Conclusions: NEDA-3 is associated with no long-term disability progression in RRMS on both low and high efficacy therapies. Further studies of early composite outcome measures incorporating easily measurable biomarkers, and longer follow-up, may help to improve on prognostic value of NEDA-3 in RRMS.
22 December 2022 in European Journal of Pediatrics